Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?
Open Access
- 9 February 2021
- journal article
- review article
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 148 (3), 145-155
- https://doi.org/10.1016/j.annder.2020.11.006
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA groupBMC Cancer, 2013
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysisJNCI Journal of the National Cancer Institute, 2010
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003
- High frequency of BRAF mutations in neviNature Genetics, 2002
- Mutations of the BRAF gene in human cancerNature, 2002